AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy
Interventions
OTHER

AlloMend® Acellular Dermal Matrix allograft

AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.

Trial Locations (1)

60435

RECRUITING

Alan H. Chen Surgical Associates, PC, Joliet

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloSource

INDUSTRY

NCT06512259 - AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction | Biotech Hunter | Biotech Hunter